Current state of gene therapy in sickle cell disease

Author:

Tang Mei San12ORCID,Shan Hua1

Affiliation:

1. Department of Pathology Stanford University School of Medicine Palo Alto California USA

2. Department of Pathology Washington University St Louis Missouri USA

Abstract

AbstractSickle cell disease (SCD) is a type of hemoglobinopathy due to an autosomal recessive genetic defect, causing significant red cell sickling, multi‐organ damage and long‐term severe morbidities. Due to its complicated care and the impact on quality of life, a curative treatment for SCD is highly desirable. In recent years, gene therapy is emerging as a curative option for SCD, where autologous haematopoietic stem cells are collected from SCD patients and genetically modified ex vivo to reduce its sickling tendency before reinfusion. Although still largely investigational, a limited number of gene therapy options have been recently granted approval for SCD patients. Published data are still currently limited, but early studies have so far demonstrated the intended outcomes of less vaso‐occlusive crisis and haemolysis. Nonetheless, despite its curative potential, larger clinical trials and longer follow‐up period are still necessary to evaluate the safety of this treatment option, especially the risk of unintended genetic modifications. Furthermore, SCD patients frequently have limited access to specialty care; hence, the issues of affordability and accessibility to SCD gene therapy must also be addressed for it to benefit the appropriate patient population.

Publisher

Wiley

Reference45 articles.

1. The Red Blood Cell—Inflammation Vicious Circle in Sickle Cell Disease

2. Food and Drug Administration.FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease. Available from:https://www.fda.gov/news‐events/press‐announcements/fda‐approves‐first‐targeted‐therapy‐treat‐patients‐painful‐complication‐sickle‐cell‐disease. Last accessed 15 Apr 2021.

3. Management of Sickle Cell Disease

4. Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia

5. Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. How I Manage Sickle Cell Retinopathy;Current Surgery Reports;2024-06-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3